B-cell Lymphoma Clinical Trials in Hangzhou, Zhejiang
7 recruitingHangzhou, Zhejiang, China
Showing 1–7 of 7 trials
Recruiting
Phase 1Phase 2
A Study to Investigate Safety and Effectiveness of BGB-16673 in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies
Refractory CancerB-cell LymphomaB-cell Malignancy+1 more
BeOne Medicines80 enrolled50 locationsNCT06634589
Recruiting
Phase 2
CD19 CAR-T Therapy for Patients With Newly Diagnosed High-risk Large B-cell Lymphoma
Large B-Cell Lymphoma (LBCL)
Zhejiang University40 enrolled1 locationNCT04661020
Recruiting
Phase 1
Clinical Study of Oncolytic Vaccinia VIrus Delivering Targeted CD19 in Vivo CAR-T/M Therapy for Refractory/Relapsed B-cell Lymphoma
Refractory/Relapsed B-cell Lymphoma
Second Affiliated Hospital, School of Medicine, Zhejiang University48 enrolled1 locationNCT07398963
Recruiting
Phase 2
A Study of Rocbrutinib in Participants With Relapse or Refractory Non-GCB Diffuse Large B-Cell Lymphoma
Diffuse Large B-Cell Lymphoma (DLBCL)
Guangzhou Lupeng Pharmaceutical Company LTD.150 enrolled41 locationsNCT07189065
Recruiting
Phase 2
Orelabrutinib Combined With Pola-R-CHP Regimen for the Treatment of Untreated Non-GCB Diffuse Large B-Cell Lymphoma
Diffuse Large B-Cell Lymphoma (DLBCL)
Second Affiliated Hospital, School of Medicine, Zhejiang University48 enrolled1 locationNCT07078500
Recruiting
Phase 1
Sequential Treatment of CD19 CARNK and 7x19 CAR-T in R/R B Cell Lymphoma
Mantle Cell Lymphoma (MCL)Primary Mediastinal B-cell Lymphoma (PMBCL)
Second Affiliated Hospital, School of Medicine, Zhejiang University52 enrolled1 locationNCT06464861
Recruiting
Phase 2
A-RGEMOX in the Treatment of Early Relapsed/Refractory DLBCL
Diffuse Large B-cell Lymphoma RecurrentDiffuse Large B Cell Lymphoma Refractory
Zhejiang Cancer Hospital41 enrolled1 locationNCT06086197